NEONC Technologies’ CEO Amirs Heshmatpour Buys 15K Shares Amid $15M Capital Raise and Promising Phase‑2a Glioma Data

Insider Confidence Amid Turbulent Trading

Amir Heshmatpour’s latest purchase on 14 September 2026—15 000 shares at $3.96—adds roughly 0.5 % to his existing stake of 3,148,000 shares. The transaction follows a rapid succession of buys that began in mid‑August, when he added 9 000 shares at $5.54 and 12 000 shares at $3.79, and culminated with a 35 000‑share purchase on 15 September at $3.30. The average price across these four recent trades is $4.20, a modest discount to the current market price of $3.31, suggesting he is taking advantage of a dip in the stock. In a sector where valuation swings are common, the steady buying pace signals a belief in the company’s long‑term value rather than a short‑term opportunistic play. The insider activity comes at a time when the company is simultaneously raising $15 million in a registered direct offering and reporting promising Phase 2a data for its intranasal glioma therapy, NEO100. These complementary events bolster the narrative that the CEO views the near‑term capital infusion and clinical data as catalysts for a future upside.

What Investors Should Take Away

For equity holders, Heshmatpour’s actions reinforce a bullish stance on NEONC’s pipeline. The company’s price‑to‑earnings ratio of –1.72 reflects a lack of profitability, but the recent clinical milestones and capital raise may be the foundation for a turnaround. The market’s current 18.67 % weekly decline and 32.59 % monthly drop could be viewed as a buying opportunity for long‑term investors who believe the Phase 2a results will translate into regulatory approval and commercialization. However, the negative earnings metric and the steep decline in share price underscore that risks remain—particularly the need for larger studies and potential regulatory hurdles.

A Profile in Confidence

Heshmatpour’s historic transaction pattern is characterized by frequent, relatively large purchases at a variety of price points. From November 2025’s 1.2 million‑share buy at an undisclosed price to the cluster of August 2026 trades, his average purchase price has hovered between $3.80 and $6.30. Unlike many insiders who sell during downturns, he has consistently added to his position even when the share price fell below $4.00. His holdings in affiliated entities—HCWG LLC, KIG LLC, and AFH Holding & Advisory—add further layers of exposure, indicating a long‑term stake that is not solely driven by short‑term market movements. The pattern suggests a management philosophy that prioritizes conviction in the company’s therapeutic pipeline over tactical trading.

Contextualizing the Buzz

The transaction took place against a backdrop of heightened social‑media chatter, with a buzz intensity of 204 % and a neutral‑to‑positive sentiment score of +50. This suggests that the insider move resonated with a community already engaged in discussions about NEONC’s clinical data and valuation. When combined with the company’s ongoing capital raise, the buying activity can be seen as a signal to the market that the management team believes the current valuation is undervaluing the underlying science and growth prospects. For investors, the convergence of insider confidence, clinical progress, and fresh capital can be an encouraging flag, but due diligence on the clinical and regulatory path remains essential.

Bottom Line

Amir Heshmatpour’s recent share purchases—performed at prices below market and in the context of a significant clinical announcement—reaffirm his belief in NEONC Technologies’ future. The insider activity, coupled with a fresh capital injection and promising Phase 2a data, points to a potential rebound for the stock. However, the company’s negative earnings, steep price declines, and the inherent uncertainties of drug development mean that investors should balance optimism with caution.